Mouse IL-9R Antibody (224325)

Detection of IL-9R by Flow Cytometry

IL9 treatment repolarizes M2 macrophages and TAMs to the M1-like phenotype. A–D, BMDMs were treated with 20 ng/mL rIL4 for 24 hours. After washing off the rIL4, the IL4-treated BMDMs were retreated with 20 ng/mL rIL9 for 48 hours. Groups of BMDMs were treated with either 20 ng/mL rIL9 or 20 ng/mL rIL4 as the positive and negative controls, respectively (A). FACS analysis of M1/M2 markers on the surface of the treated cells by staining with anti-CD80, anti-CD86, and anti-CD206. Bar graphs of the histogram analysis are shown (right; B). qPCR analysis of the mRNA expression of M1 markers (C) or M2 markers (D) in the treated groups as indicated. E–H, A total of 4 × 105 B16F10 cells were subcutaneously implanted into mice. Two weeks after the implantation, the tumor masses were collected, and TAMs were sorted using a TAM isolation kit (E). Expression of IL9R on isolated TAMs is examined by FACS (F). The isolated TAMs were treated with 100 ng rIL9 or PBS for 48 hours. The expression of M1 (CD80, CD86) and M2 (CD206 and Arg1) markers was analyzed by FACS (G) and the relative mRNA expression of other M1 markers (IL1 beta, iNOS, IL12p35) and M2 markers (IL10, Arg 1, VEGF) was analyzed by qPCR (H). *, P < 0.05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36968220), licensed under a CC-BY license. Not internally tested by R&D Systems.